Divis Laboratories:

Nirmal Bang is bullish on Divis Laboratories (DLL) and has recommended buy rating on the stock with a target price of Rs 1276 in its March 22, 2013 research report.

"DLL stock has shed 7% since its 3QFY13 results on concerns over high power costs at its Andhra Pradesh (AP) operations impacting margins. Our interaction with the company's management leads us to believe that the market may be overestimating the impact of increased power costs and we believe the current valuation of 16xFY15E EPS (20% discount to its five-year average multiple) provides an attractive entry point for investors. We have factored in our revised inhouse call on the rupee-US dollar rate of Rs52.0/$ (from Rs55.5/$ earlier) in our estimates, leading to a 2% reduction in our FY14E EPS, but retained the Buy rating on DLL with a revised target price of Rs1,276 (from Rs1,302 earlier), valuing the stock at 21xFY14E EPS of Rs 60.7 (from Rs62.0 earlier).

ICICI Bank:

Gautam Sinha Roy of Motilal Oswal is of the view that buy ICICI Bank on 5% decline.

Roy told CNBC-TV18, "As stocks are correcting few sectors where interesting buys are emerging would be private sector banks. ICICI Bank is one stock, which has corrected a lot, which one can look at if there is further correction even another 5 percent will be an interesting buy."

NHPC:

Jagannadham Thununguntla, Strategist & Head of Research at SMC Global Securities recommended holding NHPC for long term.

Thununguntla told CNBC-TV18, "If he has made up his mind that he doesn't want to see loss in NHPC then he has to still stay invested. He would have come for a short term trade, but market has forced him to become a long term trader. So, he has to stay invested. I don't think he will be making money anytime in the near future."

"Power stocks any way are not in favour of the market. Considering the current political scenario government will not be in a position to do any power reforms. NHPC is not a very under priced stock. So, considering all that, it will take considerable amount of time for him to make money on this," Thununguntla said.

Ranbaxy:

Aashish Tater, Head of Research at Fortunewizard.com advised holding Ranbaxy Labs from a medium to long term perspective.

Tater told CNBC-TV18, "Fundamentally if you see Ranbaxy is very difficult to track on quarterly results basis because there is lot of wide fluctuation in the result due to extraordinaries that the company posts normally. In the last quantitative pattern that we were looking at, it is like the stock comes around at Rs 400 odd mark, spends weeks time and then again bounces back by 10-12 percent around Rs 440-445 mark. This has happened at least 4 times in a year."

GoodReturns.in

DISCLAIMER: GoodReturns provides you with information covering shares, futures and options based on broker's reports as stated on various media. Investors are, however, warned that they should NOT take any buy or sell decision based on these views expressed in the article. Investors should consult their own financial and share advisors before taking purchase or sale decisions. GoodReturns does not take any responsibility for any losses incurred by investors who take their cues from the above article.